Literature DB >> 28237793

Design, synthesis and biological evaluation of aminobenzyloxyarylamide derivatives as selective κ opioid receptor antagonists.

Junwei Wang1, Qiao Song1, Anhua Xu1, Yu Bao1, Yungen Xu2, Qihua Zhu3.   

Abstract

Opioid receptors play an important role in both behavioral and mood functions. Based on the structural modification of LY2456302, a series of aminobenzyloxyarylamide derivatives were designed and synthesized as κ opioid receptor antagonists. The κ opioid receptor binding ability of these compounds were evaluated with opioid receptors binding assays. Compounds 1a-d showed high affinity for κ opioid receptor. Especially for compound 1c, exhibited a significant Ki value of 15.7 nM for κ opioid receptor binding and a higher selectivity over μ and δ opioid receptors compared to (±)LY2456302. In addition, compound 1c also showed potent κ antagonist activity with κ IC50 = 9.32 nM in [35S]GTP-γ-S functional assay. The potential use of the representative compounds as antidepressants was also investigated. The most potent compound 1c not only exhibited potent antidepressant activity in the mice forced swimming test, but also displayed the effect of anti-anxiety in the elevated plus-maze test.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Aminobenzyloxyarylamides; Antidepressants; LY2456302; Selectivity; κ opioid receptor antagonists

Mesh:

Substances:

Year:  2017        PMID: 28237793     DOI: 10.1016/j.ejmech.2017.02.029

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  2 in total

Review 1.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

2.  The kappa opioid receptor antagonist aticaprant reverses behavioral effects from unpredictable chronic mild stress in male mice.

Authors:  Moriah L Jacobson; Hildegard A Wulf; Caroline A Browne; Irwin Lucki
Journal:  Psychopharmacology (Berl)       Date:  2020-09-07       Impact factor: 4.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.